A Phase 2 Trial of Standard Chemotherapy, With or Without BSI-201, in Patients With Triple Negative Metastatic Breast Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00540358 |
Recruitment Status :
Completed
First Posted : October 8, 2007
Last Update Posted : December 28, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this clinical trial was to determine whether combining iniparib (BSI-201) with standard chemotherapy in estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2) negative metastatic breast cancer patients improve clinical benefit compared to treatment with standard chemotherapy alone.
Based on data generated by BiPar/Sanofi, it was concluded that iniparib does not possess characteristics typical of the poly (ADP-ribose) polymerase (PARP) inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of DNA damage) in tumor cell lines, induces cell cycle arrest in the G2/M phase in tumor cell lines, and potentiates the cell cycle effects of DNA damaging modalities in tumor cell lines. Investigations into potential targets of iniparib and its metabolites are ongoing.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Breast Cancer | Drug: gemcitabine/carboplatin Drug: iniparib | Phase 2 |
Expanded Access : An investigational treatment associated with this study is no longer available outside the clinical trial. More info ...
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 123 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase 2, Multi-center, Open-Label, Randomized Trial of Gemcitabine/ Carboplatin, With or Without BSI-201, in Patients With ER, PR and HER2-negative Metastatic Breast Cancer |
Study Start Date : | October 2007 |
Actual Primary Completion Date : | November 2009 |
Actual Study Completion Date : | June 2010 |
Arm | Intervention/treatment |
---|---|
Active Comparator: Arm G/C
Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8 of 21-day cycle(s)
|
Drug: gemcitabine/carboplatin
Gemcitabine and carboplatin administered according to instructions in the package inserts. |
Experimental: Arm G/C/I
Standard chemotherapy with gemcitabine/carboplatin on Days 1 and 8, plus iniparib on Days 1, 4, 8, and 11 of 21-day cycle(s)
|
Drug: gemcitabine/carboplatin
Gemcitabine and carboplatin administered according to instructions in the package inserts. Drug: iniparib Body weight adjusted dose 1 hour intravenous infusion Other Names:
|
- Clinical benefit rate [ Time Frame: until cut-off date established so that all patients were evaluable for primary outcome measure ]Clinical benefit rate was defined as the percentage of patients with complete response, partial response or stable disease ≥6 months.
- Objective response rate [ Time Frame: until cut-off date established so that all patients were evaluable for primary outcome measure ]Objective response rate was defined as the percentage of patients with confirmed partial response or complete response
- Progression-free survival [ Time Frame: until cut-off date established so that all patients were evaluable for primary outcome measure ]Progression-free survival was defined as the time interval from the date of randomization to the date of disease progression or the date of death due to any cause, whichever came first.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- At least 18 years of age;
- Metastatic breast cancer (Stage IV) with measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria;
- 0-2 prior chemotherapy regimens in the metastatic setting;
- Histologically documented (either primary or metastatic site) breast cancer that was ER-negative, PR-negative, and HER-2 nonoverexpressing by immunohistochemistry (0,1) or non-gene amplification by fluorescence in situ hybridization (FISH);
- Completion of prior chemotherapy at least 2 weeks prior to trial entry and recovery from toxicity of prior chemotherapy;
- Radiation therapy must have been completed at least 2 weeks prior to trial entry, and radiated lesions may not have served as measurable disease;
- Patient may have had central nervous system (CNS) metastases if he/she did not require steroids, whole brain radiation therapy (XRT), gamma/cyber knife, and brain metastases were clinically stable without symptomatic progression;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Adequate organ function defined as: absolute neutrophil count (ANC)≥1,500/mm3, platelets ≥100,000/mm3, creatinine clearance >50mL/min, ALT and AST <2.5 x upper limit of normal (ULN) (or <5 x ULN in case of liver metastases); total bilirubin <1.5 mg/dL.
- Tissue block (primary or metastatic) available for PARP and PG studies was recommended, although its absence did not exclude subjects from participating;
- Woman of child bearing potential must have had documented negative pregnancy test within two weeks of trial entry and agreed to acceptable birth control during the duration of the trial therapy;
- Signed, IRB approved written informed consent.
Exclusion Criteria:
- Lesions identifiable only by positron emission tomography (PET);
- Prior treatment with gemcitabine, carboplatin, cisplatin or iniparib;
- Major medical conditions that might have affected trial participation (uncontrolled pulmonary, renal, or hepatic dysfunction, uncontrolled infection);
- Significant history of uncontrolled cardiac disease; i.e. uncontrolled hypertension, unstable angina, recent myocardial infarction (within prior 6 months), uncontrolled congestive heart failure, and cardiomyopathy that was either symptomatic or asymptomatic but with decreased ejection fraction <45%;
- Other significant comorbid condition which the investigator felt might compromise effective and safe participation in the trial;
- Patient enrolled in another investigational device or drug trial, or was receiving other investigational agents;
- Concurrent or prior (within 7 days of trial day 1) anticoagulation therapy (low dose for port maintenance allowed);
- Concurrent radiation therapy was not permitted throughout the course of the trial;
- Inability to comply with the requirements of the trial;
- Pregnant or lactating woman;
- Leptomeningeal disease or brain metastases requiring steroids or other therapeutic intervention.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00540358
United States, Alabama | |
Research Site | |
Birmingham, Alabama, United States | |
United States, Colorado | |
Research Site | |
Denver, Colorado, United States | |
United States, Connecticut | |
Research Site | |
Torrington, Connecticut, United States | |
United States, Florida | |
Research Site | |
Ocoee, Florida, United States | |
United States, Indiana | |
Research Site | |
Indianapolis, Indiana, United States | |
United States, Kansas | |
Research Site | |
Overland Park, Kansas, United States | |
United States, Nevada | |
Research Site | |
Henderson, Nevada, United States | |
United States, New Hampshire | |
Research Site | |
Hooksett, New Hampshire, United States | |
United States, North Carolina | |
Research Site | |
Raleigh, North Carolina, United States | |
United States, Texas | |
Research Site | |
Bedford, Texas, United States | |
Research Site | |
Dallas, Texas, United States | |
Research Site | |
El Paso, Texas, United States | |
Research Site | |
Fort Worth, Texas, United States | |
Research Site | |
Houston, Texas, United States | |
Research Site | |
Tyler, Texas, United States | |
United States, Virginia | |
Research Site | |
Fairfax, Virginia, United States | |
United States, Washington | |
Research Site | |
Vancouver, Washington, United States | |
Research Site | |
Yakima, Washington, United States |
Study Director: | Clinical Sciences & Operations | Sanofi |
Responsible Party: | Sanofi |
ClinicalTrials.gov Identifier: | NCT00540358 |
Other Study ID Numbers: |
TCD11485 20070102 ( Other Identifier: BiPar ) |
First Posted: | October 8, 2007 Key Record Dates |
Last Update Posted: | December 28, 2012 |
Last Verified: | December 2012 |
Triple negative breast cancer |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Carboplatin Gemcitabine |
Iniparib Antineoplastic Agents Antimetabolites, Antineoplastic Antimetabolites Molecular Mechanisms of Pharmacological Action Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors |